Operating Grant : Methamphetamine and related psychostimulant use – Registration

Well-being, Health and Biomedical Discovery


Academic Unit: Inquire with Unit

Memorial Deadline: RGCS review not required for Registration

External Deadline: Friday 30th, August 2019


The Canadian Drug and Substances Strategy (CDSS) is the Government of Canada’s response to problematic substance use, providing an evidence-based approach to drug policy. In support of the CDSS, CIHR has launched a number of targeted funding opportunities in recent years to build the evidence base around specific substances and polysubstance use, and to rapidly deploy this knowledge to develop and implement practical policies and interventions. The current funding opportunity is focused on knowledge syntheses and implementation science approaches in the area of methamphetamine and/or related psychostimulant use more generally.

For the purposes of this funding opportunity, related psychostimulants refer to structurally or functionally related drugs that exhibit similar psychological and physiological effects to methamphetamine. These may include, but are not limited to, other forms of amphetamine (e.g., dextroamphetamine, 3,4-methylenedioxymethamphetamine [MDMA], etc.), and direct and indirect sympathomimetic psychostimulants (e.g., cocaine, methylphenidate, ephedrine, etc.). Excluded from this funding opportunity are nonsympathomimetic psychostimulants (e.g., caffeine, nicotine) and opioids, unless they are being examined in concert with eligible psychostimulants. Applicants studying related psychostimulants (i.e., eligible psychostimulants other than methamphetamine) must provide a clear justification of the relevance of the proposed psychostimulant to the Objectives of this funding opportunity.

Research Areas

This funding opportunity will support data collection, knowledge synthesis, and implementation science research in the Canadian context in the areas of:

  • Epidemiology of methamphetamine use and associated disorders, including: prevalence, incidence of methamphetamine use disorder (MUD) and methamphetamine-induced psychotic disorder, distribution of methamphetamine users, and the changing geographical and/or use patterns over time
  • Impacts of poly-substance use
  • Impacts of methamphetamine use on or near safe consumption sites
  • Impacts of methamphetamine use on the healthcare system and access to health services, including hospitalizations and clinical best practices in the management of symptoms of methamphetamine use
  • Effectiveness and adaptability of existing treatment options and approaches, including both pharmacotherapies and psychotherapies, as well as challenges in treatment
  • Safe supply and drug substitution therapies for MUD
  • Harm reduction strategies
  • Social, cultural and ethical impacts of methamphetamine use

Funds Available

  • The total amount available for this funding opportunity is $ 1,300,000, enough to fund approximately thirteen (13) grants. This amount may increase if additional funding partners participate. The maximum amount per grant is $ 100,000 per year for up to 1 year.

Additional information can be found at the CIHR webpage. 

Funding Sources

Canadian Institute of Health Research (CIHR)

This opportunity was posted by: RGCS

Last modified: August 1, 2019